This analysis reviews lornoxicam's effects on pain in rheumatic diseases, suggesting efficient pain management strategies.
Nonsteroidal anti-inflammatory drugs (NSAIDs) occupy one of the central positions in the multimodal control of acute and chronic musculoskeletal pain and have broad indications, including rheumatic diseases. Lornoxicam, an oxicam-class NSAID, is a balanced cyclooxygenase (COX)- 1/COX-2 inhibitor characterized by rapid onset of its effect, fast elimination, and a short half-life, which reduces the risk of its accumulation and provides good tolerability. Therapeutic equivalence has been demonstrated among the three lornoxicam formulations (Xefocam tablets, Xefocam injection, and Xefocam Rapid), obviating the need for dose adjustment when switching from parenteral to oral administration.
No takes yet. Share an insight, caveat, or question.
Алексеева et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: